Literature DB >> 27246513

Anti-Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter-Based Renal Denervation.

David Lang1, Alexander Nahler2, Thomas Lambert2, Michael Grund2, Jürgen Kammler2, Jörg Kellermair2, Hermann Blessberger2, Alexander Kypta2, Clemens Steinwender2, Johann Auer2,3.   

Abstract

This retrospective analysis aimed to examine off-target effects on inflammatory and renal function parameters in n=78 subsequent patients treated with renal denervation (RDN) for resistant hypertension. Ambulatory and office blood pressure (ABP/OBP), serum creatinine, glomerular filtration rate (GFR), cystatin C, C-reactive protein (CRP), interleukin-6 (IL-6), and white blood cell count (WBC) were assessed before, 6 and 12 months after RDN. ABP was significantly reduced by -8.2/-3.8 mm Hg (P=.002/.021) at 1 year after RDN, while an initial OBP reduction was not sustained during follow-up. IL-6 levels significantly decreased by -0.5 pg/mL (P=.042) and by -1.7 pg/mL (P<.001) at 6 and 12 months, baseline IL-6 levels possibly predicting ABP response to RDN (r=-0.295; P=.020). Concurrently, leukocyte count was reduced by -0.5 × 103 /μL (P=.017) and -0.8 × 103 /μL (P<.001), respectively. Serum creatinine and GFR remained unchanged, but we observed a significant increase in cystatin C by 0.04 mg/L (P=.026) and 0.14 mg/L (P<.001) at 6 and 12 months after the intervention. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27246513      PMCID: PMC8031543          DOI: 10.1111/jch.12844

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  49 in total

1.  Renal sympathetic-nerve ablation for uncontrolled hypertension.

Authors:  Markus P Schlaich; Paul A Sobotka; Henry Krum; Elisabeth Lambert; Murray D Esler
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

2.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

3.  Autonomic impairment in rheumatoid arthritis.

Authors:  Dina C Janse van Rensburg; James A Ker; Catharina C Grant; Lizelle Fletcher
Journal:  Int J Rheum Dis       Date:  2012-04-27       Impact factor: 2.454

4.  Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells.

Authors:  Galina Chipitsyna; Qiaoke Gong; Chance F Gray; Yasir Haroon; Erdinc Kamer; Hwyda A Arafat
Journal:  Endocrinology       Date:  2007-02-15       Impact factor: 4.736

5.  Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population.

Authors:  K Masuo; H Mikami; T Ogihara; M L Tuck
Journal:  Am J Hypertens       Date:  1997-01       Impact factor: 2.689

Review 6.  The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.

Authors:  Kelly Putnam; Robin Shoemaker; Frederique Yiannikouris; Lisa A Cassis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-06       Impact factor: 4.733

7.  Relationship between body mass index and anti-hypertensive efficacy of doxazosin according to a survey of Japanese patients.

Authors:  S Toyonaga; T Nakatsu; C Suezawa; H Matsubara; T Sogou; S Kusachi
Journal:  J Int Med Res       Date:  2004 Mar-Apr       Impact factor: 1.671

8.  Is serum cystatin-C a reliable marker for metabolic syndrome?

Authors:  Aude Servais; Philippe Giral; Maguy Bernard; Eric Bruckert; Gilbert Deray; Corinne Isnard Bagnis
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

9.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

10.  Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study.

Authors:  Irina Chazova; Markus P Schlaich
Journal:  Int J Hypertens       Date:  2013-02-25       Impact factor: 2.420

View more
  4 in total

Review 1.  Present Evidence of Determinants to Predict the Efficacy of Renal Denervation.

Authors:  Hao Zhou; Yanping Xu; Weijie Chen; Liang Wang; Huaan Du; Hang Liu; Zhiyu Ling; Yuehui Yin
Journal:  Int J Hypertens       Date:  2022-08-12       Impact factor: 2.434

2.  Anti-Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter-Based Renal Denervation.

Authors:  David Lang; Alexander Nahler; Thomas Lambert; Michael Grund; Jürgen Kammler; Jörg Kellermair; Hermann Blessberger; Alexander Kypta; Clemens Steinwender; Johann Auer
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-01       Impact factor: 3.738

3.  Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study.

Authors:  Marit D Solbu; Atena Miroslawska; Jon V Norvik; Bjørn O Eriksen; Terje K Steigen
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-02-16       Impact factor: 3.738

4.  Dynamics of Soluble Factors and Double-Negative T Cells Associated with Response to Renal Denervation in Resistant Hypertension Patients.

Authors:  Joana Delgado-Silva; Paulo Rodrigues-Santos; Jani-Sofia Almeida; Manuel Santos-Rosa; Lino Gonçalves
Journal:  J Pers Med       Date:  2022-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.